Erratum: Anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial

There is an error in the article by Criner and colleagues (1), published in the June 1, 2022 issue of the Journal. Because of an error by our compositor, the name of the randomized trial being discussed, BREATHE, was incorrectly defined as “Better Respiratory Education and Treatment Help Empower.” However, the BREATHE trial being discussed here is not an acronym; the name was selected in order to facilitate communication about the trial with physicians and patients. We would also like to clarify that, although there is an existing respiratory trial named Better Respiratory Education and Treatment Help Empower (BREATHE), it is not related to the trial discussed in the AJRCCM article.

For the convenience of our readers, the Journal is replacing the online version of the article with a corrected version.